CA-INCELLDX-INC.
4.10.2016 09:05:32 CEST | Business Wire | Press release
IncellDx, Inc., a single cell, precision medicine company, today announced that the international peer-reviewed medical journal Cancer Immunology, Immunotherapy has published a manuscript entitled: “Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.” Dr. Bruce Patterson, MD, Founder and CEO explained that this is a novel, single cell approach to quantifying the expression of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) tumor samples. The methodology has been validated on both fine needle aspiration (FNA) and tumor biopsies. The samples are non-enzymatically homogenized into single cell suspensions using IncellDx’s IncellPREP™ kit yielding a single-cell sample before a formalin-fixed paraffin embedded (FFPE) block is made.
As Dr. Patterson explained, “We believe this objective quantitation of PD-L1 expression in tumor and immune cells in NSCLC will allow for better prediction of patient response to the new PD-1 immunotherapies within a work flow that is suited well for primary indications where the initial diagnosis may be made using several approaches to sampling the tumor. Further, the assay and sample preparation are automated allowing for same day turn around.”
The PD-L1 and PD-1 assay is the first release of IncellDx, Inc.’s newest family of single cell, multi-parametric molecular products called OncoTect® iO for immuno-oncology in a multitude of tissue types. The paper is now available online at http://link.springer.com/article/10.1007/s00262-016-1889-3 .
About IncellDx Inc.
IncellDx, Inc. is a single cell diagnostics company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The Company develops products designed to address pressing unmet clinical needs in the advancement of cancer care in addition to its virology products.
For more information, please visit www.incelldx.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005461/en/
Contact:
IncellDx, Inc.
Chris Meda, +1-650-777-7630
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1089 Inc. Partners with Price Forbes and Oka-Lloyd's Syndicate 1922 to Launch Market-Defining First: Carbon Asset Insurance Framework for Transportation and Energy Sectors26.2.2026 23:01:00 CET | Press release
New program introduces dedicated insurance safeguards and immutable transfer infrastructure to advance fiscal maturation of global carbon markets, enabling scaled participation across world's highest-emitting sectors, Transportation and Energy. 1089 Inc., in collaboration with Price Forbes and Oka, The Carbon Insurance Company, announce launch of an insured carbon asset designed to bring institutional safeguards, disciplined financial architecture, and verifiable data integrity to carbon markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226012782/en/ 1089 Inc. is Advancing Carbon™, focused on evolving global carbon markets and decarbonizing the highest-emitting sectors on the planet: Transportation and Energy. The framework provides defined risk coverage for 1089’s CX89 Advanced Fuels Carbon Assets, underwritten by Lloyd’s Syndicate 1922 and placed with the support of Price Forbes and Oka. The program introduces ins
Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA26.2.2026 23:00:00 CET | Press release
15th QA & Dosimetry Symposium convenes medical physics and radiation therapy community in RomeTwo days of sessions span diverse topics from 24 clinical practitioners and thought leadersEvent introduces new Daily QA™ 4 Pro device and features expansion of AI-enabled solutions Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical physicists and radiation medicine professionals from nearly 40 countries. Participants from diverse clinical environments will earn continuing education credits while sharing practical insights, emerging approaches, and real-world experiences shaping the future of quality and patient safety in cancer care. Building on its legacy as a peer-driven forum with practical applications, QADS 2026 features sessions delivered by 24 speakers spanning: Future Directions in Machine and Patient QA and In-vivo Dosimetry Stereotacti
Lattice to Highlight Low Power, Edge-Ready Programmable Solutions at embedded world 202626.2.2026 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for embedded world 2026, where it will demonstrate how its low power, small form factor FPGA innovations help engineers accelerate intelligent, scalable designs from cloud to sensor. At the event, Lattice will participate in expert panel discussions, lead conference sessions, and host an interactive booth experience filled with real-world solutions for the Automotive, Industrial, and Security markets from Lattice and its innovation partners. Who: Lattice Semiconductor What / When: Lattice Booth and Demo Showcase: March 10 – 12, Hall 4, Booth #528 Expert Panel featuring Lattice Chief Strategy and Marketing Officer Esam Elashmawi March 10 at 1:30 p.m. GMT+1, Hall 3, Booth #611 Conference Sessions March 10 at 5 p.m. GMT+1 Safety & Security: “Trusted Resilience Edge – Unified FPGA-TPM for Post-Quantum Cryptography RED & Cyber Resilience Act” March 11 at 10:30 a.m. GMT+1 IoT & Connec
Omani and Jeanie Carson Named Inaugural Departure Day Dove 1 for 2026 Special Olympics Airlift, Donating Aircraft and Crew to Lead Athletes Home26.2.2026 17:00:00 CET | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that Omani and Jeanie Carson, of Omaha, Nebraska, have been named the inaugural departure day Dove 1 for the 2026 Special Olympics Airlift. The Carsons will donate their aircraft and crew to lead athletes home at the conclusion of the Games, marking the first year this honorary departure day distinction has been established. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226250477/en/ Omani and Jeanie Carson named inaugural departure day Dove 1 for 2026 Special Olympics Airlift, donating aircraft and crew to lead athletes home (Photo credit: Textron Aviation). As departure day Dove 1, the Carsons will guide the first aircraft lifting off from Minneapolis’ Twin Cities on Saturday, June 27, reuniting athletes with their families, hometowns and communities after a week of competition, determination and unforgettable experiences. This newly established
Loomis Sayles Euro Credit Team Celebrates Five-Year Milestones26.2.2026 17:00:00 CET | Press release
Loomis, Sayles & Company, the century-old investment manager with €363.8 billion in assets under management, celebrates the five-year anniversaries of its Loomis Sayles Euro Credit and Loomis Sayles Euro High Yield strategies. The Loomis Sayles Euro Credit Team, led by Co-Heads and Portfolio Managers Rik den Hartog and Pim van Mourik Broekman, manages €3.5 billion in assets across three strategies. Backed by Loomis Sayles’ industry-leading technology infrastructure and focused investment culture, the Euro Credit team seeks to generate consistent excess return versus the benchmark. The team believes this can be accomplished by using an active, conservative alpha investment process that aims to capitalize on inefficiencies in the euro credit market. Loomis Sayles Euro Credit invests primarily in investment grade, euro-denominated corporate bonds while Loomis Sayles Euro High Yield invests primarily in the BB segment of the euro-denominated high yield corporate bond market. The team’s Loo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom